{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T17:50:25Z","timestamp":1793901025373,"version":"4.8.0"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T00:00:00Z","timestamp":1740009600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T00:00:00Z","timestamp":1740009600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pharmacol Toxicol"],"DOI":"10.1186\/s40360-025-00868-5","type":"journal-article","created":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T08:10:43Z","timestamp":1740039043000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Comparison of serious adverse effects of methylphenidate, atomoxetine and amphetamine in the treatment of ADHD: an adverse event analysis based on the FAERS database"],"prefix":"10.1186","volume":"26","author":[{"given":"Linman","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongqing","family":"Lan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liuyin","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijuan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,20]]},"reference":[{"key":"868_CR1","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1016\/S0140-6736(15)00238-X","volume":"387","author":"A Thapar","year":"2016","unstructured":"Thapar A, Cooper M. Attention deficit hyperactivity disorder. Lancet. 2016;387:1240\u201350.","journal-title":"Lancet"},{"key":"868_CR2","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1192\/bjp.bp.107.048827","volume":"194","author":"V Simon","year":"2009","unstructured":"Simon V, Czobor P, B\u00e1lint S, M\u00e9sz\u00e1ros \u00c1, Bitter I. Prevalence and correlates of adult attention-deficit hyperactivity disorder: meta-analysis. Br J Psychiatry. 2009;194:204\u201311.","journal-title":"Br J Psychiatry"},{"key":"868_CR3","doi-asserted-by":"crossref","unstructured":"Song P, et al. The prevalence of adult attention-deficit hyperactivity disorder: a global systematic review and meta-analysis. J Glob Health 11:04009.","DOI":"10.7189\/jogh.11.04009"},{"key":"868_CR4","doi-asserted-by":"crossref","unstructured":"Punja S, et al. Amphetamines for attention deficit hyperactivity disorder (ADHD) in children and adolescents. Cochrane Database Syst Rev. 2016;2016:LCD009996.","DOI":"10.1002\/14651858.CD009996.pub2"},{"key":"868_CR5","doi-asserted-by":"crossref","unstructured":"Storeb\u00f8 OJ, et al. Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD). Cochrane Database Syst Rev. 2015;2015:CD009885.","DOI":"10.1002\/14651858.CD009885.pub2"},{"key":"868_CR6","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1016\/S2215-0366(18)30269-4","volume":"5","author":"S Cortese","year":"2018","unstructured":"Cortese S, et al. Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis. Lancet Psychiatry. 2018;5:727\u201338.","journal-title":"Lancet Psychiatry"},{"key":"868_CR7","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1159\/000508385","volume":"26","author":"H \u00d6zgen","year":"2020","unstructured":"\u00d6zgen H, et al. International Consensus Statement for the screening, diagnosis, and treatment of adolescents with concurrent Attention-Deficit\/Hyperactivity disorder and Substance Use Disorder. Eur Addict Res. 2020;26:223\u201332.","journal-title":"Eur Addict Res"},{"key":"868_CR8","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1136\/bmjebm-2018-111110","volume":"24","author":"E Faltinsen","year":"2019","unstructured":"Faltinsen E, et al. Updated 2018 NICE guideline on pharmacological treatments for people with ADHD: a critical look. BMJ EBM. 2019;24:99\u2013102.","journal-title":"BMJ EBM"},{"key":"868_CR9","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.eurpsy.2018.11.001","volume":"56","author":"JJS Kooij","year":"2019","unstructured":"Kooij JJS, et al. Updated European Consensus Statement on diagnosis and treatment of adult ADHD. Eur Psychiatr. 2019;56:14\u201334.","journal-title":"Eur Psychiatr"},{"key":"868_CR10","doi-asserted-by":"publisher","first-page":"e994","DOI":"10.1542\/peds.2014-3482","volume":"135","author":"R Thomas","year":"2015","unstructured":"Thomas R, Sanders S, Doust J, Beller E, Glasziou P. Prevalence of Attention-Deficit\/Hyperactivity disorder: a systematic review and Meta-analysis. Pediatrics. 2015;135:e994\u20131001.","journal-title":"Pediatrics"},{"key":"868_CR11","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1080\/15374416.2017.1417860","volume":"47","author":"ML Danielson","year":"2018","unstructured":"Danielson ML, et al. Prevalence of parent-reported ADHD diagnosis and Associated Treatment among U.S. children and adolescents, 2016. J Clin Child Adolesc Psychol. 2018;47:199\u2013212.","journal-title":"J Clin Child Adolesc Psychol"},{"key":"868_CR12","doi-asserted-by":"publisher","first-page":"4421","DOI":"10.1111\/bcp.14868","volume":"87","author":"R B\u00f6hm","year":"2021","unstructured":"B\u00f6hm R, et al. Pharmacovigilance-based drug repurposing: the search for inverse signals via OpenVigil identifies putative drugs against viral respiratory infections. Brit J Clin Pharma. 2021;87:4421\u201331.","journal-title":"Brit J Clin Pharma"},{"key":"868_CR13","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1517\/14740338.2016.1167184","volume":"15","author":"PS Ang","year":"2016","unstructured":"Ang PS, Chen Z, Chan CL, Tai BC. Data mining spontaneous adverse drug event reports for safety signals in Singapore \u2013 a comparison of three different disproportionality measures. Exp Opin Drug Saf. 2016;15:583\u201390.","journal-title":"Exp Opin Drug Saf"},{"key":"868_CR14","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1517\/14740338.2014.915938","volume":"13","author":"Y Hou","year":"2014","unstructured":"Hou Y, et al. A comparison of disproportionality analysis methods in national adverse drug reaction databases of China. Exp Opin Drug Saf. 2014;13:853\u20137.","journal-title":"Exp Opin Drug Saf"},{"key":"868_CR15","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1002\/pds.677","volume":"10","author":"SJW Evans","year":"2001","unstructured":"Evans SJW, Waller PC, Davis S. Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports. Pharmacoepidemiology Drug. 2001;10:483\u20136.","journal-title":"Pharmacoepidemiology Drug"},{"key":"868_CR16","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/pds.668","volume":"11","author":"EP Van Puijenbroek","year":"2002","unstructured":"Van Puijenbroek EP, et al. A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions. Pharmacoepidemiology Drug. 2002;11:3\u201310.","journal-title":"Pharmacoepidemiology Drug"},{"key":"868_CR17","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s002280050466","volume":"54","author":"A Bate","year":"1998","unstructured":"Bate A, et al. A bayesian neural network method for adverse drug reaction signal generation. Eur J Clin Pharmacol. 1998;54:315\u201321.","journal-title":"Eur J Clin Pharmacol"},{"key":"868_CR18","doi-asserted-by":"crossref","unstructured":"Szarfman A, Machado SG, O\u2019Neill RT. Use of Screening Algorithms and Computer Systems to Efficiently Signal Higher-Than-Expected Combinations of Drugs and Events in the US FDA??s Spontaneous Reports Database. Drug Saf. 2002;25:381\u201392.","DOI":"10.2165\/00002018-200225060-00001"},{"key":"868_CR19","doi-asserted-by":"publisher","unstructured":"Poluzzi E, Raschi E, Piccinni C, De F. Data Mining Techniques in Pharmacovigilance: Analysis of the Publicly Accessible FDA Adverse Event Reporting System (AERS). in (ed. Karahoca, A). InTech. 2012. https:\/\/doi.org\/10.5772\/50095","DOI":"10.5772\/50095"},{"key":"868_CR20","doi-asserted-by":"publisher","first-page":"1110575","DOI":"10.3389\/fphar.2023.1110575","volume":"14","author":"H Zhao","year":"2023","unstructured":"Zhao H, et al. Sodium-glucose co-transporter-2 inhibitor (SGLT2i) treatment and risk of osteomyelitis: A pharmacovigilance study of the FAERS database. Front Pharmacol. 2023;14:1110575.","journal-title":"Front Pharmacol"},{"key":"868_CR21","doi-asserted-by":"publisher","first-page":"e181471","DOI":"10.1001\/jamanetworkopen.2018.1471","volume":"1","author":"G Xu","year":"2018","unstructured":"Xu G, Strathearn L, Liu B, Yang B, Bao W. Twenty-Year Trends in Diagnosed Attention-Deficit\/Hyperactivity Disorder Among US Children and Adolescents, 1997\u20132016. JAMA Netw Open. 2018;1:e181471.","journal-title":"JAMA Netw Open"},{"key":"868_CR22","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/j.drugalcdep.2015.03.034","volume":"152","author":"EA Austic","year":"2015","unstructured":"Austic EA. Peak ages of risk for starting nonmedical use of prescription stimulants. Drug Alcohol Depend. 2015;152:224\u20139.","journal-title":"Drug Alcohol Depend"},{"key":"868_CR23","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.drugalcdep.2003.11.016","volume":"74","author":"LC Holdcraft","year":"2004","unstructured":"Holdcraft LC, Iacono WG. Cross-generational effects on gender differences in psychoactive drug abuse and dependence. Drug Alcohol Depend. 2004;74:147\u201358.","journal-title":"Drug Alcohol Depend"},{"key":"868_CR24","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1097\/ADM.0000000000000262","volume":"11","author":"T Rungnirundorn","year":"2017","unstructured":"Rungnirundorn T, Verachai V, Gelernter J, Malison RT, Kalayasiri R. Sex Differences in Methamphetamine Use and Dependence in a Thai Treatment Center. J Addict Med. 2017;11:19\u201327.","journal-title":"J Addict Med"},{"key":"868_CR25","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1080\/14740338.2023.2204228","volume":"22","author":"XQ Pan Ma","year":"2023","unstructured":"Pan Ma XQ, Tian H, Shi Q, Liu R, Zhang Y, Chen Y. High risks adverse events associated with trastuzumab emtansine and trastuzumab deruxtecan for the treatment of HER2-positive\/mutated malignancies: a pharmacovigilance study based on the FAERS database. Exp Opin Drug Saf. 2023;22:685\u201396.","journal-title":"Exp Opin Drug Saf"},{"key":"868_CR26","doi-asserted-by":"publisher","first-page":"851246","DOI":"10.3389\/fphar.2022.851246","volume":"13","author":"X Tian","year":"2022","unstructured":"Tian X, et al. Adverse Event Profiles of PARP Inhibitors: Analysis of Spontaneous Reports Submitted to FAERS. Front Pharmacol. 2022;13:851246.","journal-title":"Front Pharmacol"},{"key":"868_CR27","doi-asserted-by":"crossref","unstructured":"Warshaw EM, Squires L, Li Y, Civil R, Paller AS. Methylphenidate transdermal system: A multisite, open-label study of dermal reactions in pediatric patients diagnosed with ADHD. Prim Care Companion J Clin Psych. 2010;12:PCC.10m00996.","DOI":"10.4088\/PCC.10m00996pur"},{"key":"868_CR28","doi-asserted-by":"publisher","first-page":"e293","DOI":"10.1542\/peds.2014-0992","volume":"134","author":"E Harstad","year":"2014","unstructured":"Harstad E, Levy S, Committee on Substance Abuse. Attention-deficit\/hyperactivity disorder and substance abuse. Pediatrics. 2014;134:e293\u2013301.","journal-title":"Pediatrics"},{"key":"868_CR29","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1177\/1087054707308486","volume":"12","author":"DF Connor","year":"2008","unstructured":"Connor DF, Doerfler LA. ADHD With Comorbid Oppositional Defiant Disorder or Conduct Disorder: Discrete or Nondistinct Disruptive Behavior Disorders? J Atten Disord. 2008;12:126\u201334.","journal-title":"J Atten Disord"},{"key":"868_CR30","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1177\/1087054710370935","volume":"15","author":"R Lambek","year":"2011","unstructured":"Lambek R, et al. Executive Dysfunction in School-Age Children With ADHD. J Atten Disord. 2011;15:646\u201355.","journal-title":"J Atten Disord"},{"key":"868_CR31","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1001\/jamapsychiatry.2014.363","volume":"71","author":"T Ljung","year":"2014","unstructured":"Ljung T, Chen Q, Lichtenstein P, Larsson H. Common Etiological Factors of Attention-Deficit\/Hyperactivity Disorder and Suicidal Behavior: A Population-Based Study in Sweden. JAMA Psychiatry. 2014;71:958.","journal-title":"JAMA Psychiatry"},{"key":"868_CR32","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1111\/jcpp.12036","volume":"54","author":"S Cortese","year":"2013","unstructured":"Cortese S, et al. Practitioner review: Current best practice in the management of adverse events during treatment with ADHD medications in children and adolescents. Child Psychol Psychiatry. 2013;54:227\u201346.","journal-title":"Child Psychol Psychiatry"},{"key":"868_CR33","doi-asserted-by":"publisher","first-page":"g3769","DOI":"10.1136\/bmj.g3769","volume":"348","author":"Q Chen","year":"2014","unstructured":"Chen Q, et al. Drug treatment for attention-deficit\/hyperactivity disorder and suicidal behaviour: register based study. BMJ. 2014;348:g3769\u20133769.","journal-title":"BMJ"},{"key":"868_CR34","doi-asserted-by":"crossref","unstructured":"Banaschewski T, Roessner V, Dittmann RW, Janardhanan Santosh P, Rothenberger A. Non-stimulant medications in the treatment of ADHD. Eur Child Adolesc Psychiatry 2004:13.","DOI":"10.1007\/s00787-004-1010-x"},{"key":"868_CR35","first-page":"272","volume":"3","author":"A Preti","year":"2002","unstructured":"Preti A. Tomoxetine (Eli Lilly & Co). Curr Opin Investig Drugs. 2002;3:272\u20137.","journal-title":"Curr Opin Investig Drugs"},{"key":"868_CR36","unstructured":"European Medicines Agency finalises review of antidepressants in children and adolescents| European Medicines Agency (EMA). https:\/\/www.ema.europa.eu\/en\/news\/european-medicines-agency-finalises-review-antidepressants-children-adolescents (2005)."},{"key":"868_CR37","unstructured":"FDA Public Health Advisory. Atomoxetine (Strattera) and Suicidal Thinking in Children and Adolescents. https:\/\/www.jwatch.org\/pa200511040000009\/2005\/11\/04\/fda-public-health-advisory-atomoxetine-strattera"},{"key":"868_CR38","doi-asserted-by":"publisher","first-page":"e20153199","DOI":"10.1542\/peds.2015-3199","volume":"137","author":"S Linden","year":"2016","unstructured":"Linden S, et al. Risk of Suicidal Events With Atomoxetine Compared to Stimulant Treatment: A Cohort Study. Pediatrics. 2016;137:e20153199.","journal-title":"Pediatrics"},{"key":"868_CR39","doi-asserted-by":"publisher","first-page":"e183758","DOI":"10.1001\/jamanetworkopen.2018.3758","volume":"1","author":"TNA Winkelman","year":"2018","unstructured":"Winkelman TNA, et al. Evaluation of Amphetamine-Related Hospitalizations and Associated Clinical Outcomes and Costs in the United States. JAMA Netw Open. 2018;1:e183758.","journal-title":"JAMA Netw Open"},{"key":"868_CR40","doi-asserted-by":"publisher","first-page":"202","DOI":"10.15585\/mmwr.mm7006a4","volume":"70","author":"CL Mattson","year":"2021","unstructured":"Mattson CL, et al. Trends and Geographic Patterns in Drug and Synthetic Opioid Overdose Deaths \u2014 United States, 2013\u20132019. MMWR Morb Mortal Wkly Rep. 2021;70:202\u20137.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"868_CR41","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1001\/jamapsychiatry.2021.2588","volume":"78","author":"B Han","year":"2021","unstructured":"Han B, Compton WM, Jones CM, Einstein EB, Volkow ND. Methamphetamine Use, Methamphetamine Use Disorder, and Associated Overdose Deaths Among US Adults. JAMA Psychiatry. 2021;78:1329.","journal-title":"JAMA Psychiatry"},{"key":"868_CR42","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1111\/sltb.12442","volume":"49","author":"S Darke","year":"2019","unstructured":"Darke S, Kaye S, Duflou J, Lappin J. Completed Suicide Among Methamphetamine Users: A National Study. Suicide Life Threat Behav. 2019;49:328\u201337.","journal-title":"Suicide Life Threat Behav"},{"key":"868_CR43","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1161\/ATVBAHA.119.312461","volume":"39","author":"CG Kevil","year":"2019","unstructured":"Kevil CG, et al. Methamphetamine use and cardiovascular disease. Arterioscler Thromb Vasc Biol. 2019;39:1739\u201346.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"868_CR44","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1007\/s40263-017-0410-7","volume":"31","author":"ADDUCEconsortium The","year":"2017","unstructured":"The ADDUCEconsortium, et al. Cardiovascular Effects of Stimulant and Non-Stimulant Medication for Children and Adolescents with ADHD: A Systematic Review and Meta-Analysis of Trials of Methylphenidate, Amphetamines and Atomoxetine. CNS Drugs. 2017;31:199\u2013215.","journal-title":"CNS Drugs"},{"key":"868_CR45","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.3390\/ijerph15081789","volume":"15","author":"EF Liang","year":"2018","unstructured":"Liang EF, et al. The Effect of Methylphenidate and Atomoxetine on Heart Rate and Systolic Blood Pressure in Young People and Adults with Attention-Deficit Hyperactivity Disorder (ADHD): Systematic Review, Meta-Analysis, and Meta-Regression. IJERPH. 2018;15:1789.","journal-title":"IJERPH"},{"key":"868_CR46","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1177\/0009922810368289","volume":"49","author":"RR Silva","year":"2010","unstructured":"Silva RR, Skimming JW, Muniz R. Cardiovascular Safety of Stimulant Medications for Pediatric Attention-Deficit Hyperactivity Disorder. Clin Pediatr (Phila). 2010;49:840\u201351.","journal-title":"Clin Pediatr (Phila)"},{"key":"868_CR47","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1089\/cap.2015.0239","volume":"27","author":"JM Zito","year":"2017","unstructured":"Zito JM, Burcu M. Stimulants and Pediatric Cardiovascular Risk. J Child Adolesc Psychopharmacol. 2017;27:538\u201345.","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"868_CR48","unstructured":"Wild at heart. 34-year-old male with new onset dyspnea, heart failure and history of amphetamine use; a case report| the egyptian heart journal| full text. https:\/\/tehj.springeropen.com\/articles\/10.1186\/s43044-019-0026-y?utm_source=chatgpt.com"},{"key":"868_CR49","doi-asserted-by":"crossref","unstructured":"Amphetamine-induced coronary artery. dissection and massive aortic valve thrombus| european heart journal| oxford academic. https:\/\/academic.oup.com\/eurheartj\/article-abstract\/41\/2\/230\/5640488?redirectedFrom=fulltext%26login=false%26utm_source=chatgpt.com","DOI":"10.1093\/eurheartj\/ehz829"},{"key":"868_CR50","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1080\/08998280.2015.11929277","volume":"28","author":"AM Afzal","year":"2015","unstructured":"Afzal AM, Sarmast SA, Weber NA, Schussler JM. Spontaneous coronary artery dissection in a 22-year-old man on lisdexamfetamine. Bayl Univ Med Cent Proc. 2015;28:367\u20138.","journal-title":"Bayl Univ Med Cent Proc"},{"key":"868_CR51","doi-asserted-by":"publisher","unstructured":"Bradley SH, Lawrence N, Steele C, Mohamed Z. Precocious puberty. BMJ. 2020;l6597. https:\/\/doi.org\/10.1136\/bmj.l6597.","DOI":"10.1136\/bmj.l6597"},{"key":"868_CR52","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1196\/annals.1369.005","volume":"1074","author":"W Adriani","year":"2006","unstructured":"Adriani W, et al. Short-Term Effects of Adolescent Methylphenidate Exposure on Brain Striatal Gene Expression and Sexual\/Endocrine Parameters in Male Rats. Ann N Y Acad Sci. 2006;1074:52\u201373.","journal-title":"Ann N Y Acad Sci"},{"key":"868_CR53","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1016\/j.fertnstert.2005.03.071","volume":"84","author":"S Chatterjee-Chakrabarty","year":"2005","unstructured":"Chatterjee-Chakrabarty S, Miller BT, Collins TJ, Nagamani M. Adverse effects of methylphenidate on the reproductive axis of adolescent female rats. Fertil Steril. 2005;84:1131\u20138.","journal-title":"Fertil Steril"},{"key":"868_CR54","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1016\/j.jpurol.2012.03.017","volume":"9","author":"BD Kelly","year":"2013","unstructured":"Kelly BD, Lundon DJ, McGuinness D, Brady CM. Methylphenidate-induced erections in a prepubertal child. J Pediatr Urol. 2013;9:e1\u20132.","journal-title":"J Pediatr Urol"},{"key":"868_CR55","unstructured":"Eli Lilly and Company. Strattera. https:\/\/pi.lilly.com\/us\/strattera-pi.pdf"},{"key":"868_CR56","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1016\/j.jpeds.2006.01.035","volume":"148","author":"JR Lim","year":"2006","unstructured":"Lim JR, Faught PR, Chalasani NP, Molleston JP. Severe liver injury after initiating therapy with atomoxetine in two children. J Pediatr. 2006;148:831\u20134.","journal-title":"J Pediatr"},{"key":"868_CR57","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1080\/15563650600795644","volume":"45","author":"SD Stojanovski","year":"2007","unstructured":"Stojanovski SD, Casavant MJ, Mousa HM, Baker P, Nahata MC. Atomoxetine-induced hepatitis in a child. Clin Toxicol. 2007;45:51\u20135.","journal-title":"Clin Toxicol"}],"container-title":["BMC Pharmacology and Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40360-025-00868-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40360-025-00868-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40360-025-00868-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T08:10:50Z","timestamp":1740039050000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpharmacoltoxicol.biomedcentral.com\/articles\/10.1186\/s40360-025-00868-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,20]]},"references-count":57,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["868"],"URL":"https:\/\/doi.org\/10.1186\/s40360-025-00868-5","relation":{},"ISSN":["2050-6511"],"issn-type":[{"value":"2050-6511","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,20]]},"assertion":[{"value":"14 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable. This study was deemed non-human subject related research.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"38"}}